NCT06553638

Brief Summary

50 patients with a diagnosis of MPN will have an assessment of b2microglobuline at diagnosis and after 1 year. b2mic value decrease will be compared to treatment response.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
0mo left

Started Aug 2024

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress99%
Aug 2024May 2026

First Submitted

Initial submission to the registry

August 12, 2024

Completed
Same day until next milestone

Study Start

First participant enrolled

August 12, 2024

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 14, 2024

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2026

Last Updated

August 14, 2024

Status Verified

April 1, 2024

Enrollment Period

1.8 years

First QC Date

August 12, 2024

Last Update Submit

August 12, 2024

Conditions

Myeloproliferative Neoplasm

Outcome Measures

Primary Outcomes (1)

  • b2mic decrease level between responders and non-responders

    1 year

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with a new diagnosis of MPN

You may qualify if:

  • MPN patient diagnosed at one of the participating centers
  • over 18 yo

You may not qualify if:

  • Not able to consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chu Brest

Brest, 29609, France

Location

Biospecimen

Retention: SAMPLES WITH DNA

serum, blood DNA.

MeSH Terms

Conditions

Myeloproliferative Disorders

Condition Hierarchy (Ancestors)

Bone Marrow DiseasesHematologic DiseasesHemic and Lymphatic Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 12, 2024

First Posted

August 14, 2024

Study Start

August 12, 2024

Primary Completion (Estimated)

May 31, 2026

Study Completion (Estimated)

May 31, 2026

Last Updated

August 14, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will share

All collected data that underlie results in a publication

Shared Documents
STUDY PROTOCOL
Time Frame
Data will be available beginning three years and ending fifteen years following the final study report completion
Access Criteria
Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement

Locations

FR(1)